| Recruiting | U69-CART-Cells For R/R T-ALL Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma | Phase 1 | 2026-06-25 |
| Not Yet Recruiting | Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL Acute Lymphobkastic Leukemia | Phase 2 | 2026-06-01 |
| Recruiting | MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib Acute Myeloid Leukemia (AML), FLT3-ITD Mutation, Allogeneic Hematopoietic Cell Transplantation (HCT) | Phase 3 | 2026-05-01 |
| Recruiting | A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patient Relapsed or Refractory Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome) | N/A | 2026-04-01 |
| Recruiting | U96-CAR-T-Cells For R/R B-ALL Relapsed or Refractory B Cell Leukemia and Lymphoma | Phase 1 | 2026-03-30 |
| Recruiting | BY002 IIT Study in R/R Acute Leukemia Acute Leukemia, KMT2A Rearrangements or NPM1 Mutations Acute Leukemia | Phase 1 | 2026-03-15 |
| Not Yet Recruiting | Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Dia Acute Myeloid Leukemia (AML) | Phase 3 | 2026-03-10 |
| Not Yet Recruiting | Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer | Phase 2 | 2026-03-01 |
| Recruiting | Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients Oral Mucositis, Stomatitis, Gastrointestinal Mucositis | Phase 2 | 2026-02-15 |
| Not Yet Recruiting | Venetoclax Combined With Azacitidine for Consolidation Therapy in AML Acute Myeloid Leukemia, Consolidation Therapy, Venentoclax | Phase 2 | 2026-02-01 |
| Recruiting | Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA MDS (Myelodysplastic Syndrome), Aplastic Anemia (AA) | Phase 2 | 2026-01-31 |
| Recruiting | Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL Peripheral T Cells Lymphoma (PTCL) | Phase 2 | 2026-01-15 |
| Recruiting | Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | 2026-01-01 |
| Recruiting | Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | 2025-11-30 |
| Recruiting | Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma | Phase 4 | 2025-11-01 |
| Recruiting | Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. Marginal Zone Lymphoma (MZL) | Phase 2 | 2025-10-24 |
| Recruiting | A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia Aplastic Anaemia | N/A | 2025-10-01 |
| Recruiting | Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML Acute Myeloid Leukemia (AML), CEBPA Mutation, Unfit, New-diagnosis AML | Phase 1 / Phase 2 | 2025-09-15 |
| Recruiting | Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Primacy Immune Thrombocytopenia | N/A | 2025-09-01 |
| Recruiting | Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Adult T-cell Leukemia/Lymphoma | Phase 2 | 2025-09-01 |
| Recruiting | Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia Menin Inhibitors, Post Hematopoietic Stem Cell Transplantation, Maintenance Therapy | Phase 2 | 2025-08-01 |
| Recruiting | A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia Relapsed/Refractory Plasma Cell Leukemia, Relapsed/Refractory Multiple Myeloma | EARLY_Phase 1 | 2025-07-23 |
| Recruiting | A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis Atopic Dermatitis | Phase 1 | 2025-07-14 |
| Not Yet Recruiting | RN1201 Injection in the Treatment of Antibody-Mediated Diseases Refractory Immune-mediated Platelet Transfusion Refractoriness, Relapsed or Refractory Immune Thrombocytopenia | Phase 1 | 2025-07-10 |
| Active Not Recruiting | Generation of Reactive T Cells Based on Tumor Whole Cell Antigen Nanovaccines Lung Cancer (NSCLC) | — | 2025-07-10 |
| Enrolling By Invitation | Clinical Study of 68Ga-labeled Novel Nectin-4 Bicyclic Peptide PET/CT for Imaging of Solid Tumors With High Ne Solid Tumors With High Expression of Nectin4 | N/A | 2025-07-03 |
| Not Yet Recruiting | A Study on the Use of Sulpegfilgrastim to Prevent the Incidence of Neutropenia With Infection in Newly Diagnos Multiple Myeloma, DRD, Sulpegfilgrastim | N/A | 2025-06-30 |
| Recruiting | A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Asthma Asthma | Phase 1 | 2025-06-20 |
| Not Yet Recruiting | Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis Hemophagocytic Lymphohistiocytosis (HLH) | Phase 2 / Phase 3 | 2025-06-01 |
| Not Yet Recruiting | The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethaso Multiple Myeloma, Carfilzomib, Daratumumab | N/A | 2025-06-01 |
| Recruiting | a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia Acute Myeloid Leukemia, IDH1 Gene Mutation, Ivosidenib | Phase 2 | 2025-06-01 |
| Recruiting | Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab | Phase 2 | 2025-05-17 |
| Recruiting | A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia Acute Myeloid Leukemia With T(8;21)(Q22;Q22), Acute Myeloid Leukemia With T(16;16)(P13;Q22), KIT Gene Mutation | Phase 1 / Phase 2 | 2025-05-15 |
| Not Yet Recruiting | A Clinical Trial Evaluating the Safety Tolerability, Radiation Absorption Dose, Distribution, PET Imaging and Multiple Myeloma (MM) | N/A | 2025-05-01 |
| Recruiting | Dapagliflozin in Allo-HCT for aGVHD Graft-versus-host Disease (GVHD) | Phase 2 | 2025-04-26 |
| Not Yet Recruiting | Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants Wit AML, Adult | N/A | 2025-02-15 |
| Recruiting | Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Le Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Transplantation, Stem Cell | Phase 2 | 2025-01-30 |
| Recruiting | Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refrac Primary Central Nervous System Lymphoma (PCNSL) | N/A | 2025-01-02 |
| Recruiting | Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Cytomegalovirus Infections, CMV | N/A | 2024-12-16 |
| Recruiting | Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NH Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) | N/A | 2024-12-10 |
| Not Yet Recruiting | The Real-world Study of Rimegepant Treatment in Female Migraine Patients of China Migraine, Migraine Prophylaxis | — | 2024-12-01 |
| Recruiting | Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leuke B-Cell Acute Lymphoblastic Leukemia, Adult | EARLY_Phase 1 | 2024-12-01 |
| Recruiting | A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R Relapsed or Refractory Acute Myeloid Leukemia | N/A | 2024-12-01 |
| Not Yet Recruiting | BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients T-Cell Lymphocytic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Total Body Irradiation | Phase 3 | 2024-12-01 |
| Recruiting | Efficacy of Repeated Transcranial Magnetic Stimulation Combined With a Live Probiotic Tablet (Combined Bifidob Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea (IBS-D), Repetitive Transcranial Magnetic Stimulation (rTMS) | Phase 1 | 2024-12-01 |
| Recruiting | The Impact of Local Anesthetic Solution Temperature on Epidural-related Maternal Fever Epidural Related Maternal Fever, Analgesia, Epidural, Fever | N/A | 2024-11-30 |
| Recruiting | Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL Diffuse Large B-cell Lymphoma(DLBCL) | Phase 2 | 2024-11-10 |
| Recruiting | Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnose Diffuse Large B-Cell Lymphoma | N/A | 2024-11-01 |
| Recruiting | Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients Peripheral T-cell Lymphoma | N/A | 2024-11-01 |
| Recruiting | Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients CD30+ Peripheral T-cell Lymphoma | N/A | 2024-11-01 |
| Recruiting | Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients Newly Diagnosed Multiple Myeloma | — | 2024-09-10 |
| Not Yet Recruiting | Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia Leukemia, Myeloid, Acute, B-cell Acute Lymphoblastic Leukemia | EARLY_Phase 1 | 2024-09-01 |
| Recruiting | Evaluation of CMV/EBV-CMI in Haploid HSCT Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Epstein-Barr Virus Infections | — | 2024-08-13 |
| Not Yet Recruiting | Modified DEP Regimens for the Treatment of Hemophagocytic Lymphohistiocytosis Hemophagocytic Lymphohistiocytoses | Phase 4 | 2024-08-01 |
| Recruiting | Lf-rTMS Attenuates Visceral Pain in Irritable Bowel Syndrome With Diarrhea Repetitive Transcranial Magnetic Stimulation, Chronic Visceral Pain, Functional Magnetic Resonance Imaging | N/A | 2024-08-01 |
| Recruiting | Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/ Acute Myeloid Leukemia, Adult, Newly Diagnosed | Phase 2 | 2024-07-29 |
| Recruiting | A Single-Arm, Prospective Study of TBI+BUMEL as Conditioning for SCT2 in Patients With Malignant Hematologic D Malignant Hematological Diseases | N/A | 2024-07-10 |
| Not Yet Recruiting | CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma NHL | Phase 2 | 2024-07-10 |
| Active Not Recruiting | Repeated Transcranial Magnetic Stimulation Relieves Maternal Care Impairment Maternal Care Patterns, Repetitive Transcranial Magnetic Stimulation (rTMS), Functional Magnetic Resonance Imaging | N/A | 2024-06-14 |
| Recruiting | Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection Newly Diagnosed, High Risk, MRD | Phase 4 | 2024-06-12 |
| Recruiting | A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Ch B-cell Non-Hodgkin Lymphoma | — | 2024-06-01 |
| Active Not Recruiting | N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy Thrombotic Microangiopathy | Phase 2 / Phase 3 | 2024-05-01 |
| Recruiting | Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL B-cell Acute Lymphoblastic Leukemia | Phase 2 | 2024-04-25 |
| Unknown | CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia | Phase 2 | 2024-04-20 |
| Completed | Repetitive Transcranial Magnetic Stimulation Attenuates Visceral Pain in Irritable Bowel Syndrome With Diarrhe Irritable Bowel Syndrome, Repetitive Transcranial Magnetic Stimulation, Chronic Visceral Pain | N/A | 2024-04-01 |
| Recruiting | Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL B-cell Acute Lymphoblastic Leukemia | Phase 1 | 2024-04-01 |
| Recruiting | VA vs DA for Newly Diagnosed Hig-risk AML Acute Myeloid Leukemia | Phase 2 / Phase 3 | 2024-04-01 |
| Unknown | Effects of an Oral Multi-vitamin Carbohydrate Beverage on Intraoperative Nausea and Vomiting Nausea and Vomiting, Aspiration, Intraoperative | N/A | 2024-04-01 |
| Recruiting | Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients Acute T Cell Lymphoblastic Leukemia, Haploidentical Hematopoietic Stem Cell Transplantation, Cord Blood | Phase 3 | 2024-04-01 |
| Recruiting | Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients Intermediate Risk Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia | Phase 2 | 2024-02-15 |
| Recruiting | Chemotherapy-free Regimen of Venetoclax, Azacitidine Plus Orebatinib (VAO Regimen) for Newly Diagnosed ph+ALL Ph-Positive Acute Lymphoblastic Leukemia | Phase 2 | 2024-02-01 |
| Recruiting | VAC Regimen for AML Patients Who Failed to Response to VA Regimen Acute Myeloid Leukemia | Phase 2 | 2024-02-01 |
| Recruiting | Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma Lymphoma, B-Cell, Autologous Stem Cell Transplantation | Phase 2 | 2024-01-01 |
| Active Not Recruiting | Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diag Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | EARLY_Phase 1 | 2024-01-01 |
| Recruiting | Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML Acute Myeloid Leukemia | Phase 2 | 2024-01-01 |
| Recruiting | TBI/Flu/Bu/Mel Combined With Secondary UCBT in Patients With Hematological Malignancies Who Relapsed After All Hematopoietic Malignancy, Relapse/Recurrence, Hematopoietic Stem Cell Transplantation | N/A | 2023-11-01 |
| Withdrawn | An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Ref Relapsed/Refractory Multiple Myeloma | Phase 1 | 2023-10-09 |
| Unknown | Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies Hematological Malignancies, Chimeric Antigen Receptor T-cell Therapy | — | 2023-09-03 |
| Unknown | A Registry for Patients With Systemic Mastocytosis in China Systemic Mastocytoses | — | 2023-09-01 |
| Completed | A Clinical Study Comparing the Effectiveness and Safety of Three Surgical Pathways for Laparoscopic Total Hyst Benign Tumor of Uterus, Surgical Approaches, Enhanced Recovery After Surgery | N/A | 2023-09-01 |
| Enrolling By Invitation | Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients Acute Promyelocytic Leukemia | Phase 2 / Phase 3 | 2023-08-01 |
| Unknown | The Use of N-acetylcysteine for Thrombotic Events After Allogenic Hematopoietic Stem Cell Transplantation Thrombotic Disorder | Phase 3 | 2023-08-01 |
| Not Yet Recruiting | Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT Poor Graft Function | Phase 3 | 2023-08-01 |
| Not Yet Recruiting | Decitabine for Poor Graft Function Post Allo-HSCT Poor Graft Function | Phase 3 | 2023-07-01 |
| Not Yet Recruiting | A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL Philadelphia-Positive ALL | Phase 2 | 2023-07-01 |
| Enrolling By Invitation | Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL Effects of Chemotherapy, Safety Issues | Phase 2 | 2023-07-01 |
| Recruiting | TFBC Combined With UCBT in the Treatment of High-risk Malignant Hematological Diseases Hematopoietic Stem Cell Transplantation, Malignant Hematological Diseases | N/A | 2023-06-01 |
| Unknown | Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients Relapsed/Refractory AML | N/A | 2023-05-01 |
| Unknown | Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning Multiple Myeloma | Phase 4 | 2023-04-17 |
| Recruiting | CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia Multiple Myeloma, Plasma Cell Leukemia | N/A | 2023-04-12 |
| Completed | Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China CMV Infection, Hematopoietic Stem Cell Transplantation | — | 2023-04-01 |
| Unknown | The Relationship Between Self-disclosure, Perceived Social Support and Reproductive Concerns Survivors of Young Male Cancer Survivors | — | 2023-03-20 |
| Recruiting | PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT Acute Myeloid Leukemia | N/A | 2023-03-15 |
| Unknown | Efficacy and Safety of Autologous Cryopreserved Platelets in Patients With PTR Platelet Transfusion Refractoriness | N/A | 2023-03-01 |
| Unknown | Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients Acute Myeloid Leukemia (Relapsed/Refractory) | Phase 2 | 2023-03-01 |
| Recruiting | Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML Acute Myeloid Leukemia | Phase 2 / Phase 3 | 2023-03-01 |
| Recruiting | Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients Diffuse Large B Cell Lymphoma | N/A | 2023-01-04 |
| Unknown | M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia Acute Leukemia | Phase 2 / Phase 3 | 2023-01-01 |
| Unknown | Deep Learning in Classifying Bowel Obstruction Radiographs Digestive System Disease, Polyp of Colon, Bowel Disease | — | 2022-12-31 |
| Unknown | Clinical Study of rATG Individualized Administration in Haploidentical Hematopoietic Stem Cell Transplantation Hematopoietic Stem Cell Transplantation, Acute Leukemia | Phase 4 | 2022-12-20 |
| Unknown | Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphom Relapsed/Refractory Peripheral T-cell Lymphoma | Phase 2 | 2022-12-14 |
| Unknown | ThisCART19A for B-NHL Relapsed After Auto-CAR T CAR, B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 | 2022-12-01 |
| Unknown | ThisCART19A Bridging to alloHSCT for R/R B-ALL CAR, Refractory Acute Lymphoblastic Leukemia, Relapsed Adult ALL | Phase 1 | 2022-12-01 |
| Recruiting | Construction of a Database for TMA Thrombotic Microangiopathies | — | 2022-12-01 |
| Completed | The Optimal Dose of Indomethacin Suppository for Preventing Post-ERCP Pancreatitis Pancreatitis, Cholangiopancreatography, Endoscopic Retrograde, Indomethacin | N/A | 2022-11-01 |
| Unknown | Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML Acute Myeloid Leukemia | Phase 3 | 2022-10-31 |
| Completed | The Use of Eltrombopag Post HSCT in BMFD Stem Cell Transplant Complications | Phase 2 / Phase 3 | 2022-10-22 |
| Recruiting | Construction of a Database for TTP TTP - Thrombotic Thrombocytopenic Purpura | — | 2022-10-20 |
| Recruiting | CAV Regimen for R/R AML Acute Myeloid Leukemia | Phase 2 | 2022-10-01 |
| Recruiting | CAV Regimen for R/R Ph- B-ALL Acute Lymphoblastic Leukemia | N/A | 2022-10-01 |
| Unknown | Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma | — | 2022-10-01 |
| Not Yet Recruiting | Aspirin for Prophylaxis of TTP Thrombotic Thrombocytopenic Purpura | Phase 2 / Phase 3 | 2022-10-01 |
| Unknown | Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients Diffuse Large B-Cell Lymphoma | Phase 2 | 2022-09-30 |
| Recruiting | Olverembatinib for FGFR1-rearranged Neoplasms Myeloproliferative Neoplasm, Acute Leukemia | Phase 2 | 2022-09-01 |
| Unknown | Observational Study for the Evaluation of Incidence of Systemic Mastocytosis in t(8;21) Acute Myeloid Leukemia Systemic Mastocytosis With AHNMD, Acute Myeloid Leukemia With T(8;21)(Q22;Q22) | — | 2022-09-01 |
| Unknown | This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Relapsed and/or Refractory Multiple Myeloma | EARLY_Phase 1 | 2022-08-10 |
| Unknown | Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involve Safety and Efficacy | Phase 4 | 2022-08-01 |
| Unknown | Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL Diffuse Large B-Cell Lymphoma | Phase 2 | 2022-07-27 |
| Unknown | Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS CMV Infection, Hematopoietic Stem Cell Transplantation | Phase 2 | 2022-07-07 |
| Unknown | GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | N/A | 2022-07-01 |
| Recruiting | AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission Acute Myeloid Leukemia (AML) in Remission | Phase 2 / Phase 3 | 2022-06-25 |
| Unknown | Avapritinib in CBF-AML With KIT Mutations Core Binding Factor Acute Myeloid Leukemia, KIT Mutation-Related Tumors | Phase 2 | 2022-06-01 |
| Active Not Recruiting | Cohort Construction and Prognostic Model Construction for Multiple Myeloma Multiple Myeloma | — | 2022-05-03 |
| Completed | Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Pat Philadelphia Chromosome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | 2022-05-01 |
| Completed | Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001# Relapsed/Refractory Multiple Myeloma | Phase 1 | 2022-04-27 |
| Recruiting | Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients T-cell Acute Lymphoblastic Leukemia, Recruiting | Phase 2 | 2022-04-01 |
| Unknown | Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Myelodysplastic/Myeloproliferative Neoplasms, Adult | Phase 2 | 2022-04-01 |
| Recruiting | Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Acute Monocytic Leukemia, Newly Diagnosed | Phase 2 | 2022-03-01 |
| Unknown | Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Phase 2 | 2022-02-10 |
| Unknown | Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Phase 2 | 2022-02-10 |
| Unknown | Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL B-cell Acute Lymphoblastic Leukemia | Phase 2 | 2022-02-01 |
| Unknown | Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndr Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | 2022-01-20 |
| Unknown | Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSC Allogeneic Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia | Phase 2 | 2022-01-20 |
| Unknown | Anti-BCMA CAR T-Cell Therapy for R/R ITP ITP | Phase 2 | 2022-01-01 |
| Unknown | PET / CT Imaging and Safety in Patients With Lymphoma Treated With CD19 Car-t Cells Lymphoma | N/A | 2022-01-01 |
| Unknown | Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | 2022-01-01 |
| Withdrawn | Clinical Study on the Impact of Covid-19 Vaccine on Allogeneic Hematopoietic Stem Cell Transplantation Hematologic Diseases | — | 2022-01-01 |
| Unknown | Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2021-12-31 |
| Unknown | GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Aplastic Anemia | Phase 2 | 2021-12-30 |
| Completed | Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation Acute-graft-versus-host Disease, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 3 | 2021-12-22 |
| Unknown | Clinical Efficacy and Safety of CD47 Monoclonal Antibody Combined With Azacitidine in the Treatment of Recurre Patients With Recurrent Acute Myelogenous Leukemia After Transplantation | N/A | 2021-12-14 |
| Unknown | A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients Non-Small Cell Lung Cancer | N/A | 2021-12-06 |
| Unknown | Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma, Intestinal Flora | N/A | 2021-12-01 |
| Not Yet Recruiting | AZA Combined With NAC for PIT After HSCT Thrombocytopenia, Isolated, Stem Cell Transplant Complications | Phase 2 | 2021-12-01 |
| Unknown | A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagn Newly Diagnosed Multiple Myeloma | N/A | 2021-12-01 |
| Unknown | Avatrombopag to Promote Platelet Engraftment After Allo-HSCT Platelet Disorder | Phase 2 | 2021-12-01 |
| Unknown | Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction Therapies Acute Myeloid Leukemia, Adult, Gut Microbiota | — | 2021-11-01 |
| Completed | Venetoclax Based Regimen for R/R T-ALL Acute T-Lymphocytic Leukemia | Phase 2 | 2021-11-01 |
| Unknown | A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myelo Relapsed and/or Refractory Multiple Myeloma | N/A | 2021-10-28 |
| Completed | CAV Regimen Bridging to HSCT for R/R AL Acute Leukemia, Relapsed, Acute Leukemia Refractory | Phase 2 | 2021-10-01 |
| Active Not Recruiting | New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML | Phase 2 | 2021-09-01 |
| Unknown | Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients Ankylosing Spondylitis | — | 2021-09-01 |
| Unknown | Application of Nanopore Sequencing in Newly Diagnosed Acute Myeloid Leukemia Patients With Bloodstream Infecti Blood Stream Infection, Gut Microbiota, Acute Myeloid Leukemia | — | 2021-08-05 |
| Unknown | CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma Refractory and Relapsed T Cell Lymphoma | Phase 2 | 2021-08-05 |
| Unknown | PBMC Collection for Production of UCAR T Cells Peripheral Blood Mononuclear Cell | N/A | 2021-07-14 |
| Unknown | Outcomes of Patients After Allo-HSCT With Decitabine and NAC Engraft Failure, Relapse, GVHD | Phase 3 | 2021-07-01 |
| Unknown | Abatacept s.c. for aGVHD Prevention in Haplo-HCT Abatacept, Acute-graft-versus-host Disease, Haplo-identical HCT | Phase 1 / Phase 2 | 2021-06-01 |
| Unknown | Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia T Lymphoblastic Leukemia/Lymphoma, Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2021-06-01 |
| Unknown | Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD Safety and Efficacy | Phase 1 / Phase 2 | 2021-05-31 |
| Unknown | Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line Therapy EBV Infection | Phase 4 | 2021-05-15 |
| Unknown | The Effect of Precise Aerosol Inhalation Nursing on Sputum Excretion in Elderly Patients With Lung Surgery Inhalation | N/A | 2021-05-08 |
| Unknown | PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AM Immunotherapy, Refractory Leukemia, Relapsed Adult AML | Phase 3 | 2021-05-01 |
| Unknown | Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS AML, MDS, Old Age; Debility | Phase 2 / Phase 3 | 2021-05-01 |
| Unknown | Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC. Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | 2021-05-01 |
| Unknown | Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL Platelet Transfusion Refractoriness, Acute Leukemia in Remission | Phase 1 / Phase 2 | 2021-04-29 |
| Unknown | Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL Non-GCB/ABC Diffuse Large B-Cell Lymphoma | Phase 2 | 2021-04-01 |
| Recruiting | Efficacy and Safety of Auto-FMT in Preventing aGVHD Graft Versus Host Disease, Acute | N/A | 2021-03-01 |
| Unknown | Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features Acute Myeloid Leukemia, Adult | Phase 2 | 2021-02-20 |
| Unknown | the Effect of Acupoint Application Combined With Ear Acupoint Embedding in Patients After Esophageal Cancer Su Traditional Chinese Medicine | N/A | 2021-01-01 |
| Unknown | Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD Safety and Efficacy | Phase 4 | 2020-12-15 |
| Recruiting | Relationship Between "FODMAPs" and "GVHD" Graft Versus Host Disease | — | 2020-12-01 |
| Unknown | Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM Safety and Efficacy | Phase 1 | 2020-12-01 |
| Unknown | Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma | Phase 2 | 2020-12-01 |
| Unknown | Target Busulfan Exposure in Children With HSCT in China Hematopoietic Stem Cell Transplantation | — | 2020-11-01 |
| Recruiting | Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients Acute Myeloid Leukemia | Phase 2 | 2020-11-01 |
| Unknown | Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia CML, Chronic Phase; TKI | — | 2020-09-25 |
| Unknown | Alterations in Intestinal Microbiota, Metabolites, and Immune Cells in Allo-HSCT Graft Vs Host Disease | — | 2020-09-01 |
| Unknown | A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | — | 2020-09-01 |
| Unknown | A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 2 | 2020-08-01 |
| Completed | Effect of Bronchial Artery Protection on Cough After Thoracoscopic Lobectomy Cough | N/A | 2020-08-01 |
| Unknown | Effectiveness of NextDose for Warfarin Dose Individualization Thrombosis Embolism | Phase 4 | 2020-08-01 |
| Unknown | Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma Untreated Mantle Cell Lymphoma | Phase 2 | 2020-07-27 |
| Completed | Sequential CD19/CD22 CAR-T Cell Therapy Following ASCT Large B-cell Lymphoma, CAR T Cell Therapy, Auto Stem Cell Transplant | Phase 2 | 2020-02-24 |
| Recruiting | CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL B-cell Acute Lymphoblastic Leukemia | Phase 2 | 2020-01-19 |
| Unknown | To Explore the Related Factors of Cough After Thoracoscopic Pneumonectomy Cough | — | 2019-12-01 |
| Recruiting | Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High- Multiple Myeloma | Phase 1 / Phase 2 | 2019-07-15 |
| Unknown | Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia Safety and Efficacy | Phase 4 | 2019-06-01 |
| Unknown | Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-AL B-cell Acute Lymphoblastic Leukemia | Phase 2 | 2019-04-01 |
| Unknown | Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients Acute Myeloid Leukemia, Induction Chemotherapy | Phase 3 | 2019-04-01 |
| Unknown | Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60 Acute Myeloid Leukemia, Induction Chemotherapy | Phase 3 | 2019-04-01 |
| Unknown | Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer Non-Small-Cell Lung | N/A | 2019-03-30 |
| Unknown | Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myelo Induction Chemotherapy, Acute T-Lymphocytic Leukemia, T-cell Lymphoblastic Lymphoma Leukemia | Phase 3 | 2019-01-01 |
| Unknown | 89Zr-KN035 PET Imaging in Patients With Advanced Solid Tumors Solid Tumor, Adult | N/A | 2018-11-12 |
| Unknown | Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCT Acute Myeloid Leukemia | — | 2018-10-15 |
| Recruiting | Nutritional Status of Patients After Hematopoietic Stem Cell Transplantation Nutrition, Hematopoietic Stem Cell Transplantation | — | 2018-10-01 |
| Completed | A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multip Myeloma | — | 2018-08-01 |
| Completed | The Affection of Two Chest Management for Enhanced Recovery Program After Video-assisted Thoracoscopic Lobecto Chest Tube | N/A | 2018-07-28 |
| Active Not Recruiting | Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT Safety and Efficacy | Phase 1 / Phase 2 | 2018-02-20 |
| Unknown | Eltrombopag For Secondary Poor Graft Function Post Allogeneic Hematopoietic Stem Cell Transplantation Poor Graft Function | Phase 2 | 2018-02-01 |
| Completed | CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Acute Myeloid Leukemia, Relapsed, Adult | Phase 2 | 2018-01-01 |
| Completed | A Safety and Efficacy Study of NAC in Patients With TA-TMA Thrombotic Microangiopathies, Hematologic Diseases | Phase 3 | 2017-11-01 |
| Unknown | Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients Multiple Myeloma | Phase 3 | 2017-10-19 |
| Unknown | Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo- Acute Myeloid Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning | Phase 2 / Phase 3 | 2017-09-01 |
| Recruiting | CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia, Adult B-Cell | Phase 1 / Phase 2 | 2017-07-10 |
| Unknown | CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapesd or Refractory Acute Myeloid Leukemia Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2017-07-01 |
| Unknown | Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML) Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2017-07-01 |
| Unknown | Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Pred Peripheral T Cell Lymphoma | N/A | 2017-06-15 |
| Completed | Haplo HCT vs Haplo-cord HCT for Patients With AML Hematopoietic Stem Cell Transplantation, Haplo-identical Donor, Cord Blood Unit | Phase 3 | 2017-06-01 |
| Unknown | CAR-T for R/R B-NHL Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, CAR - T CD19/CD20/CD22/CD30 | Phase 2 | 2017-06-01 |
| Recruiting | FMT in Gut aGVHD Treated Acute-graft-versus-host Disease | — | 2017-05-16 |
| Unknown | PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia Treatment | Phase 1 / Phase 2 | 2016-10-01 |
| Recruiting | Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory a Multiple Myeloma | Phase 1 / Phase 2 | 2016-09-01 |
| Completed | Risk Factors for Predictors of In-hospital Death in Acute Fulminant Myocarditis Viral Myocarditis, Cardio-Renal Syndrome, Risk Factor, Cardiovascular | — | 2016-01-01 |
| Active Not Recruiting | CAR-T Cell Therapy Targeting to CD19 for R/R ALL Acute Lymphoblastic Leukemia with Failed Remission | Phase 1 / Phase 2 | 2015-12-01 |
| Completed | Prospective Study of Patients With Thrombocytopenia Following HSCT Thrombocytopenia, Hematologic Diseases | Phase 3 | 2015-10-01 |
| Unknown | PDD vs PAD to Treat Initially Diagnosed MM Multiple Myeloma | Phase 4 | 2015-10-01 |
| Unknown | Hemostatic Complications in Hematopoietic Stem Cell Transplantation Hemostatic Disorders | — | 2014-12-01 |
| Completed | Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia | Phase 3 | 2014-12-01 |
| Unknown | Sorafenib to Treat FLT3-ITD AML Acute Myeloid Leukemia, FLT3-ITD Mutation | — | 2014-06-01 |
| Unknown | Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in Chi Multiple Myeloma Proved by Laboratory Tests | Phase 1 / Phase 2 | 2014-05-01 |
| Unknown | Haplo-SCT vs ASCT With or Without Decitabine in AML CR1 Acute Myeloid Leukemia | Phase 3 | 2014-02-01 |
| Unknown | Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Acute Myelocytic Leukemia, Myelodysplastic Syndromes | Phase 2 / Phase 3 | 2013-01-01 |
| Enrolling By Invitation | Follow-up Study of ICUS and CCUS Patients Myelodysplastic Syndromes | — | 2011-01-01 |
| Unknown | Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Trans Higher-risk Myelodysplastic Syndrome, Relapsed /Refractory Acute Myeloid Leukemia | Phase 4 | 2009-09-01 |